CoChat

Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction?

Ganz, Patricia A., Bower, J.E., Kwan, L., Castellon, S.A., Silverman, D.H.S., Geist, C., Breen, E.C., Irwin, M.R., Cole, S.W. · 2013 · Brain, Behavior, and Immunity
Cited by 140

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbi.2012.07.015

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 50

  1. Ahles, 2002, Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma, J. Clin. Oncol., 20, 485, 10.1200/JCO.2002.20.2.485 · DOI · Paper page
  2. Ahles, 2008, Cognitive function in breast cancer patients prior to adjuvant treatment, Breast Cancer Res. Treat., 110, 143, 10.1007/s10549-007-9686-5 · DOI · Paper page
  3. Ahles, 2007, Candidate mechanisms for chemotherapy-induced cognitive changes, Nat. Rev. Cancer, 7, 192, 10.1038/nrc2073 · DOI · Paper page
  4. Ahles, 2010, Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve, J. Clin. Oncol., 28, 4434, 10.1200/JCO.2009.27.0827 · DOI · Paper page
  5. Alexander, 2009, A comparison of the characteristics of disease-free breast cancer survivors with or without cancer-related fatigue syndrome, Eur. J. Cancer, 45, 384, 10.1016/j.ejca.2008.09.010 · DOI · Paper page
  6. Bower, 2002, Fatigue and proinflammatory cytokine activity in breast cancer survivors, Psychosom. Med., 64, 604, 10.1097/00006842-200207000-00010 · DOI · Paper page
  7. Bower, 2007, Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids, Brain Behav. Immun., 21, 251, 10.1016/j.bbi.2006.08.001 · DOI · Paper page
  8. Bower, 2007, Cancer-related fatigue: links with inflammation in cancer patients and survivors, Brain Behav. Immun., 21, 863, 10.1016/j.bbi.2007.03.013 · DOI · Paper page
  9. Bower, 2008, Behavioral symptoms in patients with breast cancer and survivors, J. Clin. Oncol., 26, 768, 10.1200/JCO.2007.14.3248 · DOI · Paper page
  10. Bower, 2011, Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism?, J. Clin. Oncol., 29, 3517, 10.1200/JCO.2011.36.1154 · DOI · Paper page
  11. Butler, 1994, Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer, J. Clin. Oncol., 12, 2621, 10.1200/JCO.1994.12.12.2621 · DOI · Paper page
  12. Capuron, 2004, Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy, Brain Behav. Immun., 18, 205, 10.1016/j.bbi.2003.11.004 · DOI · Paper page
  13. Castellon, 2004, Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen, J. Clin. Exp. Neuropsychol., 26, 955, 10.1080/13803390490510905 · DOI · Paper page
  14. Collado-Hidalgo, 2006, Inflammatory biomarkers for persistent fatigue in breast cancer survivors, Clin. Cancer Res., 12, 2759, 10.1158/1078-0432.CCR-05-2398 · DOI · Paper page
  15. Collado-Hidalgo, 2008, Cytokine gene polymorphisms and fatigue in breast cancer survivors: early findings, Brain Behav. Immun., 22, 1197, 10.1016/j.bbi.2008.05.009 · DOI
  16. Deprez, 2012, Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning, J. Clin. Oncol., 30, 274, 10.1200/JCO.2011.36.8571 · DOI · Paper page
  17. Donovan, 2004, Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer, J. Pain Symptom Manage., 28, 373, 10.1016/j.jpainsymman.2004.01.012 · DOI · Paper page
  18. Ferguson, 2007, Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy, J. Clin. Oncol., 25, 3866, 10.1200/JCO.2007.10.8639 · DOI · Paper page
  19. Friston, K.J., Ashburner, J.T., Kiebel, S.J., Nichols, T.E., Penny, W.D., 2007. Statistical Parametric Mapping: The Analysis of Functional Brain Images. Academic Press, Burlington, MA.
  20. Ganz, P.A., Castellon, S.A., Silverman, D.H.S., Kwan, L., Bower, J.E., Irwin, M.R., Cole, S.W., 2011a. Does circulating tumor necrosis factor (TNF) play a role in post-chemotherapy cerebral dysfunction in breast cancer survivors (BCS)? In: Abstract presented at Annual Meeting of the American Society of Clinical Oncology, Chicago, June 3, 2011. · doi:10.1200/jco.2011.29.15_suppl.9008
  21. Ganz, 2011, Physical and psychosocial recovery in the year after primary treatment of breast cancer, J. Clin. Oncol., 29, 1101, 10.1200/JCO.2010.28.8043 · DOI · Paper page
  22. Ganz, P.A., Kwan, L., Castellon, S.A., Bower, J.E., Silverman, D.H.S., Irwin, M.R., Cole, S.W., 2012. Cognitive complaints in breast cancer patients: associations with therapy and cytokine markers. In: Abstract presented at the International Cognition and Cancer Task Force Conference Meeting, Paris, March 16, 2012.
  23. Jenkins, 2006, A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer, Br. J. Cancer, 94, 828, 10.1038/sj.bjc.6603029 · DOI · Paper page
  24. Joshi, 2010, Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrain, Neuroscience, 166, 796, 10.1016/j.neuroscience.2010.01.021 · DOI
  25. Joshi, 2005, Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain, Free Radic. Res., 39, 1147, 10.1080/10715760500143478 · DOI · Paper page
  26. Kesler, 2011, Prefrontal cortex and executive function impairments in primary breast cancer, Arch. Neurol., 68, 1447, 10.1001/archneurol.2011.245 · DOI · Paper page
  27. McDonald, 2010, Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study, Breast Cancer Res. Treat., 123, 819, 10.1007/s10549-010-1088-4 · DOI · Paper page
  28. Meyers, 2000, Neurocognitive dysfunction in cancer patients, Oncology (Huntingt), 14, 75
  29. Meyers, C.A., 2008. How chemotherapy damages the central nervous system. J. Biol. 7 (4), 11 (Epub April 22). · DOI
  30. Miller, 2008, Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer, J. Clin. Oncol., 26, 971, 10.1200/JCO.2007.10.7805 · DOI · Paper page
  31. Orre, 2009, Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue, Brain Behav. Immun., 23, 868, 10.1016/j.bbi.2009.04.003 · DOI
  32. Phillips, 2011, Cognitive functioning after cancer treatment, Cancer, 118, 1925, 10.1002/cncr.26432 · DOI
  33. Rasgon, 2005, Estrogen use and brain metabolic change in postmenopausal women, Neurobiol. Aging, 26, 229, 10.1016/j.neurobiolaging.2004.03.003 · DOI
  34. Saykin, 2006, Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI, Neurology, 67, 834, 10.1212/01.wnl.0000234032.77541.a2 · DOI · Paper page
  35. Schagen, 2006, Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients, J. Natl. Cancer Inst., 98, 1742, 10.1093/jnci/djj470 · DOI · Paper page
  36. Schagen, 1999, Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma, Cancer, 85, 640, 10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G · DOI · Paper page
  37. Shai, 2005, A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes, Diabetes Care, 28, 1376, 10.2337/diacare.28.6.1376 · DOI
  38. Silverman, 2007, Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy, Breast Cancer Res. Treat., 103, 303, 10.1007/s10549-006-9380-z · DOI · Paper page
  39. Squire, 1979, Memory complaints after electroconvulsive therapy: assessment with a new self-rating instrument, Biol. Psychiatry, 14, 791
  40. Stein, 2000, Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer, J. Pain Symptom Manage., 19, 436, 10.1016/S0885-3924(00)00142-1 · DOI
  41. Syrjala, 2011, Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years, J. Clin. Oncol., 29, 2397, 10.1200/JCO.2010.33.9119 · DOI
  42. Talairach, J., Tournoux, P., 1988. Co-planar stereotaxic atlas of the human brain. 3-Dimensional Proportional System: An Approach to Cerebral Imaging. Thieme, New York.
  43. Tannock, 2004, Cognitive impairment associated with chemotherapy for cancer: report of a workshop, J. Clin. Oncol., 22, 2233, 10.1200/JCO.2004.08.094 · DOI · Paper page
  44. van Dam, F.S., Schagen, S.B., Muller, M.J., Boogerd, W., vd Wall, E., Droogleever Fortuyn, M.E., Rodenhuis, S., 1998. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J. Natl. Cancer Inst. 90, 210–218. · DOI · Paper page
  45. Vardy, 2008, Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop, Ann. Oncol., 19, 623, 10.1093/annonc/mdm500 · DOI · Paper page
  46. Wang, 2010, Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy, Brain Behav. Immun., 24, 968, 10.1016/j.bbi.2010.03.009 · DOI · Paper page
  47. Wang, 2012, Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy, Brain Behav. Immun., 26, 699, 10.1016/j.bbi.2011.12.007 · DOI
  48. Wefel, 2004, The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial, Cancer, 100, 2292, 10.1002/cncr.20272 · DOI · Paper page
  49. Wefel, 2008, Neuropsychological sequelae of non-central nervous system cancer and cancer therapy, Neuropsychol. Rev., 18, 121, 10.1007/s11065-008-9058-x · DOI
  50. Wefel, 2010, Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer, Cancer, 116, 3348, 10.1002/cncr.25098 · DOI · Paper page

Cited by

See all 140

Metadata

Authors
Ganz, P. A., Bower, J. E., Kwan, L., Castellon, S. A., Silverman, D. H. S., Geist, C., Breen, E. C., Irwin, M. R., & Cole, S. W.
Venue
Brain, Behavior, and Immunity
Publisher
Elsevier BV
Published
2013-03
Volume
30
Pages
S99-S108
ISSN
0889-1591
Cited by
140
References
10
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.